Aim This review aims to summarize and discuss some of the most relevant clinical trials in
epidemiology, diagnostics, and treatment of hypertension published in 2020 and 2021. Data …

Arterial hypertension is the most prevalent modifiable risk factor associated with
cardiovascular morbidity and mortality. Although antihypertensive drugs are widely …

Background Endovascular renal denervation reduces blood pressure in patients with mild-to-
moderate hypertension, but its efficacy in patients with true resistant hypertension has not …

Renal denervation is a promising new non-pharmacological treatment for resistant
hypertension. However, there is a lack of data from Asian patients. The REQUIRE trial …

Hypertensive individuals are at an increased risk of developing heart disease and stroke.
Adopting healthy lifestyles, such as being active on≥ 4 days per week, weight-loss in the …

Abstract This ESH Position Paper 2021 with updated proposed recommendations was
deemed necessary after the publication of a set of new pivotal sham-controlled randomized …

Proceedings from the 3rd European Clinical Consensus Conference for clinical trials in
device-based hypertension therapies | European Heart Journal | Oxford Academic Skip to Main …

The clinical implications of hypertension in addition to a high prevalence of both
uncontrolled blood pressure and medication nonadherence promote interest in developing …

Importance Although early trials of endovascular renal denervation (RDN) for patients with
resistant hypertension (RHTN) reported inconsistent results, ultrasound RDN (uRDN) was …

Importance Ultrasound renal denervation (uRDN) was shown to lower blood pressure (BP)
in patients with uncontrolled hypertension (HTN). Establishing the magnitude and …